Clovis Oncology Stock News

Clovis Oncology, Inc. (NASDAQ: CLVS) shares are trading lower on Tuesday.Late Monday, the company announced a common stock offering of $85 million. The company announced the pricing of 11 million shar

Today, we revisit Clovis Oncology, whose stock has been one of the many in the space that have disappointed over the past few years. However, the company just g

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share, before underwri

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of common stock. Clovis Oncology intends to offer,...

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of common stock.

Clovis' (CLVS) PARP inhibitor, Rubraca, receives approval from the FDA as monotherapy to treat BRCA-mutant metastatic castration-resistant prostate cancer.

On Friday, Clovis Oncology (NASDAQ: CLVS) gained Food and Drug Administration approval of Rubraca for patients with metastatic castration-resistant prostate tumors that have BRCA mutations. By itself

Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the U.S. Food and Drug Administration (FDA) approved Rubraca® (rucaparib) tablets for the treatment of adult patients with a deleterious BRC

Clovis Oncology (CLVS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Shares of small-cap cancer company Clovis Oncology (NASDAQ: CLVS) gained a whopping 33.7% over the course of April, according to data from S&P; Global Market Intelligence. Clovis' stock regained it